CS3006 / CStone Pharma - LARVOL DELTA

A Study of CS3006 in Subjects With Locally Advanced or Metastatic Solid Tumors (clinicaltrials.gov) - P1; N=18; Completed; Sponsor: CStone Pharmaceuticals; Active, not recruiting ➔ Completed; Trial completion date: Oct 2020 ➔ Jun 2020

Clinical • Trial completion • Trial completion date • Oncology • Solid Tumor

Study of CS3006 in Subjects With Locally Advanced or Metastatic Solid Tumors (clinicaltrials.gov) - P1; N=17; Completed; Sponsor: CStone Pharmaceuticals; Recruiting ➔ Completed; Trial completion date: Jan 2021 ➔ May 2020; Trial primary completion date: Aug 2020 ➔ May 2020

Clinical • Trial completion • Trial completion date • Trial primary completion date • Oncology • Solid Tumor

A Study of CS3006 in Subjects With Locally Advanced or Metastatic Solid Tumors (clinicaltrials.gov) - P1; N=18; Active, not recruiting; Sponsor: CStone Pharmaceuticals; Recruiting ➔ Active, not recruiting; N=36 ➔ 18

Clinical • Enrollment change • Enrollment closed

Study of CS3006 in Subjects With Locally Advanced or Metastatic Solid Tumors (clinicaltrials.gov) - P1; N=17; Recruiting; Sponsor: CStone Pharmaceuticals; N=60 ➔ 17

Clinical • Enrollment change

A Study of CS3006 in Subjects With Locally Advanced or Metastatic Solid Tumors (clinicaltrials.gov) - P1; N=36; Recruiting; Sponsor: CStone Pharmaceuticals; N=60 ➔ 36; Trial completion date: Apr 2020 ➔ Oct 2020

Enrollment change • Trial completion date